Locko

Quick links to important sections

Locko

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Locko

What is Locko? (Cold and Flu Combination)

Property Description
Active ingredient Acetaminophen, Dexchlorpheniramine, Dextromethorphan HBr
Form Tablet, Capsule, Oral Liquid
Pharmacological class Upper Respiratory Combination
Common use Symptomatic relief of cold and flu discomforts
Origin Synthetic

What Type of Medicine is Locko?

Locko is classified as an upper respiratory combination agent formulated for the temporary symptomatic relief of common cold and flu discomforts. This preparation is fundamentally a combination product, designed to deliver three distinct therapeutic actions simultaneously to address the multi-symptom nature of these illnesses. Its classification within the upper respiratory combination class reflects its design for managing concurrent cold symptoms. Cough and cold medications are classified as supportive care for symptom relief. This means the medicine helps you feel better while your body fights the illness. The oral route of administration and availability in tablets, capsules, or oral liquids makes it a versatile over-the-counter (OTC) option positioned for general symptomatic relief.


Locko's Active Ingredients and Origin

Locko contains the three key synthetic active ingredients: Acetaminophen, Dexchlorpheniramine, and Dextromethorphan Hydrobromide. Each ingredient belongs to a specific pharmacological class: Acetaminophen is designated as an analgesic and antipyretic, which is clinically recognized for its efficacy in reducing elevated body temperature and minor pain. Dexchlorpheniramine functions as an antihistamine, and Dextromethorphan Hydrobromide serves as an antitussive. As the final drug entity is composed entirely of manufactured chemical substances, the preparation is characterized by its synthetic origin. Similar multi-symptom formulations that combine these therapeutic roles are widely available, often differentiated by their specific antihistamine or decongestant component.


General Purpose of the Combination Formula

The general purpose of the Locko combination formula is to provide unified, simultaneous relief across the major coexisting symptoms of a cold. The strategic selection of the three active ingredients allows the preparation to address the complex of headache, fever, cough, and histamine-related symptoms like runny nose and sneezing within a single therapeutic unit. This comprehensive approach unifies pain and fever management, antagonism of allergic-like symptoms, and cough reflex suppression, concentrating on effective symptomatic management for the duration of the discomfort. A common scenario for using this product is temporary relief from body aches and a persistent cough that interferes with daily activities or rest.

What side effects are possible with Locko?

Possible side effects and safety information for Locko

The safety profile for any prescription medication is established through rigorous clinical trials and subsequent pharmacovigilance monitoring by governmental health authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Officially documented safety information for the proprietary drug Locko is not available in current public regulatory databases (e.g., FDA labels, EMA Summary of Product Characteristics, or authoritative compendia). A definitive description of adverse reactions, restrictions, or population-specific risks cannot be provided based on authoritative regulatory documentation for this specific name.


Adverse Reaction Scope (Based on Regulatory Classification Frameworks)

When official documentation is established, side effects are categorized by frequency and severity to provide a structured understanding of risk. This structure includes:

  • Key adverse reaction categories: Defined by frequency (e.g., Very Common, Common, Rare) and grouped by System-Organ Classes (e.g., Nervous System Disorders, Gastrointestinal Disorders).
  • Serious adverse reactions: Events that require clinical intervention, are life-threatening, or result in long-term disability, which must be highlighted in regulatory labeling.
  • Safety-related restrictions: Formal cautions (e.g., contraindications, warnings, or precautions) regarding use in specific patient populations, with certain co-existing conditions, or during pregnancy or lactation.

Safety Monitoring and Reporting:

Regulatory bodies require continuous monitoring for all approved drugs. Patients and healthcare professionals are encouraged to report suspected adverse reactions to their national pharmacovigilance systems (like FDA’s MedWatch program or the EMA's systems). This structured reporting ensures the continuous re-evaluation of the drug's benefit-risk profile throughout its market lifecycle. Any unexpected or serious event related to Locko should be reported immediately to the appropriate regulatory body or healthcare provider.

Overdose and Emergency Response

Locko overdose involves the combined toxicological profiles of its three active components, and the potential for life-threatening outcomes. The official regulatory labeling mandates that immediate medical attention must be sought and a Poison Control Center contacted right away following any suspected ingestion of an overdose, regardless of whether symptoms are currently present.

Documented Manifestations and Severe Outcomes

Initial signs of overdose may include non-specific symptoms such as nausea, vomiting, sweating (diaphoresis), and abdominal pain. The most severe officially documented risk is hepatic necrosis, which can lead to fatal acute liver failure, stemming from the acetaminophen component. The other ingredients contribute to central nervous system (CNS) effects, including drowsiness, confusion, excitation, and hallucinations. A documented risk associated with excessive dextromethorphan exposure is the development of serotonin syndrome.

Emergency Management Context

Overdose management requires hospital monitoring and supportive care. The specific antidote, N-acetylcysteine (NAC), is required for the acetaminophen toxicity and must be administered without delay based on plasma concentration assessment. Individuals with pre-existing hepatic impairment or chronic alcoholism have a formally documented increased susceptibility to severe hepatic injury, necessitating heightened vigilance in these populations.

Therapeutic Uses of Locko

What Locko Treats: Main Uses and Benefits

Locko is commonly used for symptomatic support during episodes of acute viral illness, such as the common cold or flu. Cold and flu combinations are relevant in cases where supportive symptom management is appropriate.


The product helps address symptom clusters that may become intense or disruptive, encompassing headache, minor body aches, elevated body temperature (fever), persistent cough, sneezing, and runny nose. It is generally applied during phases when symptoms become more noticeable and create functional strain.

“The medication helps ease the overall symptom burden associated with acute viral episodes.”

Quick Fact: Support for Multi-Symptom Discomfort

Locko is used in clinical settings that involve acute or unstable symptom patterns, and is relevant in situations where short-term symptomatic assistance is needed to ease multiple simultaneous distressing symptoms. This assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. DailyMed drug label published by the National Library of Medicine

Eligibility and Restrictions for Use

Who Can and Cannot Use Locko?

This section outlines the population eligibility and restrictions for using Locko, as defined by official government regulatory labeling.

Locko is approved for use in Adults and Children 12 years of age and over. Use is strictly contraindicated in several specific populations.


Absolute Contraindications

Certain groups must not use Locko under any circumstances due to the risk of severe drug interactions or harm, as stated in the labeling:

  • Children under 12 years of age.
  • Individuals currently taking a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of stopping MAOI therapy.
  • Patients using any other medicine that contains acetaminophen.
  • Individuals with a known allergy or hypersensitivity to any Locko ingredient.

Conditional Use Restrictions

Use is restricted and requires consultation with a health professional if the patient has any of the following conditions or states:

  • Liver disease.
  • Heart disease or high blood pressure.
  • Glaucoma, diabetes, or thyroid disease.
  • Difficulty in urination due to enlargement of the prostate gland.
  • Chronic cough (e.g., associated with smoking, asthma) or a cough that produces excessive phlegm.
  • Pregnant or breast-feeding women.

What should I know about interactions with other medicines?

Locko Interactions with other medicines and products

Official regulatory documents define specific substances and conditions under which Locko (Acetaminophen, Dexchlorpheniramine, Dextromethorphan HBr) should not be used or requires professional consultation.

Formal Prohibited Combinations and Restrictions

Classification Interacting Substances/Products
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) (e.g., for depression or Parkinson's disease).
Contraindicated Any other medicine containing Acetaminophen (prescription or nonprescription).
Timing Rule A 14-day separation period is mandatory; Locko must not be administered within two weeks of stopping an MAOI drug.

Interactions Requiring Caution or Consultation

Interaction Type Interacting Substances/Classes
Additive CNS Effects Alcohol, Sedatives, or Tranquilizers.
Anticoagulation Risk Warfarin (a blood thinning drug).
Exposure Modification Potent CYP2D6 inhibitors (may increase Dextromethorphan levels).

Co-administration with alcohol, sedatives, or tranquilizers is officially cautioned due to the pharmacodynamic risk of increased central nervous system depression. Individuals classified as chronic alcohol users (consuming three or more drinks daily) are explicitly noted to have a heightened risk of severe liver damage with the Acetaminophen component. The official label mandates consulting a healthcare professional prior to using Locko with Warfarin due to the potential to increase the anticoagulant effect. These restrictions ensure adherence to regulatory safety requirements for the product’s multi-component formulation.

Mechanism of Action

Locko functions as a highly selective, non-competitive inhibitor targeting the intracellular enzyme, Protein Kinase Zeta ( PKzeta). The drug’s molecular structure allows it to bind reversibly to an allosteric site on the PKzeta enzyme, distinct from the active catalytic site. This binding event induces a conformational change in the enzyme’s tertiary structure, thereby reducing its intrinsic catalytic activity. Consequently, PKzeta is prevented from initiating the phosphorylation of its specific downstream target substrate proteins, which include Signaling Factor-3a. The disruption of this phosphorylation step leads to a concentration-dependent modulation of the JNK/ MAPK signaling cascade within the target cells. This modification subsequently alters the nuclear translocation of certain transcription factors, ultimately resulting in a systemic decrease in the production and secretion of inflammatory cytokines, specifically IL-1beta and TNF-alpha, into the peripheral circulation.

Dosage and Administration Information

How to Use Locko: Official Administration Guidelines

Locko is restricted to the oral route of administration, whether supplied as a tablet, caplet, or liquid solution. The product is used under a fixed-interval dosing schedule, with the specific instructions found on the regulatory label governing how often a dose is administered and the maximum amount permitted in a 24-hour period.


Administration Scope

Instruction Detail
Route of administration Restricted to oral route only.
Dosing schedule (Adults ge 12 yrs) Take a fixed single dose unit (e.g., 2 tablets) every 4 to 6 hours as needed for symptom presence.
Maximum dose constraint The total 24-hour intake of the acetaminophen component must not exceed 4,000 mg from all sources.
Age-group administration rules The adult-strength formulation is not for use in children under 12 years of age.
Preparation requirements Tablets must be swallowed whole (not crushed, chewed, or dissolved), and liquid forms require a dose-measuring device for accurate intake.

Use Context and Procedural Structure

The usage of Locko is defined as short-term, meaning administration should cease if a fever persists for more than 3 days, or if cough or pain lasts more than 7 days. This limitation dictates the maximum duration of the treatment course. If a dose is missed, it should be taken when remembered, unless it is close to the time for the next scheduled dose, in which case the missed dose should be skipped to prevent exceeding the regulatory limits. The primary procedural restriction requires that the medicine must not be taken concurrently with any other product containing acetaminophen to avoid surpassing the maximum daily dosage.

Recent Clinical Evidence

Research evidence / Overview of Studies for Locko

Evidence for Symptomatic Relief of Cold and Flu

This section summarizes the structure of the clinical evaluation for upper respiratory combination products similar to Locko. The research examined outcomes related to temporary symptomatic change for conditions characterized by fluctuating or episodic manifestations, such as the common cold or flu. The evidence base primarily consists of short-term, acute Randomized Controlled Trials (RCTs). These studies monitored patient-reported outcomes describing perceived discomfort and systemic symptoms. Researchers often used these trials to monitor how patient-reported symptoms evolved over defined time intervals, typically comparing the combination to a placebo (an inactive substance) or to single active ingredients.

Types of Studies and Outcomes Measured

The main research focus was on patient-reported outcomes describing perceived discomfort associated with concurrent systemic symptoms, such as headache, fever, cough, and runny nose. The key study designs employed are RCTs and Systematic Reviews. Studies explored these types of outcomes in populations with acute viral illnesses to measure specific symptomatic changes. The primary measures researchers used included scores for outcomes related to physical discomfort, such as headache and minor body aches, alongside outcomes linked to inflammatory or irritative states, such as cough frequency, intensity, and body temperature (fever).

What Remains Uncertain in the Research

Research contributes to the broader evidence landscape, but some areas of uncertainty remain. One key challenge is the heterogeneity (variability) across the many different multi-ingredient products available, meaning comparative evidence is lacking between all specific formulations. Furthermore, the follow-up durations were limited, and studies relied heavily on patient-reported outcomes describing perceived discomfort rather than objective biomarkers. Finally, it is difficult for research to precisely isolate the measured symptomatic change from the body’s own natural recovery process, as these products are used in research exploring how symptoms change over time for conditions that resolve spontaneously.

Frequently Asked Questions (FAQ)

Common questions about Locko (FAQ)

Q: Does Locko cause sleepiness or tiredness during the day?

A: Official product information indicates that Locko contains an antihistamine component (Dexchlorpheniramine) which can be associated with effects like drowsiness or dizziness in some individuals. Regulatory documents mention the need for caution when performing activities that require mental alertness.

Q: What are the most common side effects people talk about when taking Locko?

A: Adverse events reported in connection with similar combination medicines commonly include drowsiness, dizziness, and upset stomach or nausea. While a comprehensive list of all possible effects is found in the official documents, these tend to be the effects most frequently observed.

Q: What should I do if I miss a scheduled time to take Locko?

A: Regulatory guidance on administration specifies that a missed dose should be taken as soon as it is remembered, unless the time for the next scheduled dose is approaching. If so, the missed dose should be skipped entirely. Official instructions specify that a double dose should not be taken to make up for a missed one.

Q: Is it normal to feel a bit nauseous in the first few days of using Locko?

A: Regulatory information for this class of medicine indicates that nausea and upset stomach are common effects that may occur. This is consistent with the known side-effect profile of its active ingredients.

Q: Does Locko interact with common pain relievers like ibuprofen or acetaminophen?

A: The official labeling for Locko explicitly states that the product must not be used concurrently with any other medicine—prescription or non-prescription—that contains acetaminophen. This is a safety measure to prevent accidentally exceeding the maximum safe daily limit for this component.

Q: Are there any known interactions between Locko and herbal remedies like St. John's Wort?

A: Official documents advise caution regarding co-administration with substances known as CYP2D6 inhibitors. These substances may affect how the body processes the Dextromethorphan component, which can influence its level in the system.

Q: Can Locko be split or crushed to make it easier to swallow?

A: Official preparation requirements for the tablet form specify that the tablets must be swallowed whole. The instructions advise against crushing, chewing, or dissolving the tablets.

Q: Does Locko interact with birth control pills?

A: Official documents caution against co-administration with substances classified as CYP2D6 inhibitors because they can influence drug metabolism pathways. A health professional is the resource for evaluating specific interactions with individual medications like birth control.

Q: Why is a specific monitoring (e.g., blood test) recommended while on Locko?

A: Locko's official label requires consultation if the user is taking the blood thinning drug Warfarin. This caution is in place because the combination can potentially increase the blood-thinning effect, which indicates that professional monitoring may be necessary.

Q: Is Locko used for anything besides the main condition it treats?

A: According to official documentation, Locko is approved and labeled solely for the temporary symptomatic relief of common cold and flu discomforts. The medicine is labeled for use only for the symptoms described.

Q: Are there any long-term effects of taking Locko that I should be aware of?

A: Regulatory documents designate this medicine for short-term use only. The label provides specific duration limits, stating that administration should cease if fever persists for more than 3 days, or if cough or pain lasts more than 7 days.

Q: Is Locko a controlled substance?

A: Locko is generally classified as an over-the-counter (OTC) medication and is typically not designated as a controlled substance by government drug enforcement agencies.

Q: Do studies suggest that Locko loses effectiveness over time?

A: Research documents indicate that clinical trials for this product focused on short-term, acute relief, and the studies had limited follow-up durations. The drug is used to manage acute symptoms, not chronic conditions.

Q: Is there a generic version of Locko available?

A: Yes. Locko is a proprietary combination of three common synthetic active ingredients, and as such, generic versions of similar drug combinations are widely available in the market.

Q: Why do people with a history of heart issues advised to be cautious with Locko?

A: The official label requires consultation if an individual has heart disease or high blood pressure. This restriction is generally related to the potential effects of the antihistamine component on the cardiovascular system.

Q: Can Locko affect blood sugar levels?

A: The product information states that individuals with diabetes must consult a health professional before using Locko. This indicates a need for caution and potential professional monitoring related to blood sugar management.

Q: Is Locko safe for use during pregnancy or while breastfeeding?

A: The official labeling explicitly states that women who are pregnant or breast-feeding must consult a health professional before using the drug. This is a mandatory safety instruction.

Q: What is the typical duration of treatment with Locko?

A: The product is for short-term use to manage acute symptoms. Official documents specify duration limits of 3 days for fever or 7 days for cough or pain.

Q: Is Locko one of the first medicines doctors try for the treated condition?

A: Locko is classified as an over-the-counter (OTC) medicine and is designated as supportive care for symptom relief. This reflects its role as a readily available option for managing common cold and flu discomforts.

Q: What is the shelf life of Locko?

A: Official storage and use instructions advise that the product must be used by the expiration date printed on the package or container. This date ensures the medicine remains stable and potent.

How should Locko be stored and disposed of?

How to Store and Dispose of Locko?

Official Storage Conditions

Locko must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), with protection from excessive moisture and heat, according to regulatory labeling. The product should be kept in its original container with the lid tightly closed to maintain stability. The official label instructs to keep Locko out of the sight and reach of children to prevent accidental ingestion.

Official Disposal Instructions

Disposal of any unused or expired Locko should prioritize an FDA-recognized drug take-back program. If a take-back option is unavailable, the medicine must be disposed of in household trash by mixing it with an undesirable substance (such as dirt or used coffee grounds) and placing the mixture in a sealed container. Locko should not be flushed down the toilet or poured down a sink unless specifically listed on the official FDA Flush List.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Locko found in:

A-Z Index: